Dr. Kumar on the Design of a Phase II Trial of MLN9708

Video

In Partnership With:

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

In this follow-up to studies previously presented, researchers analyzed patients with relapsed multiple myeloma in order to identify potential activity. In the study, 32 patients who were pretreated with immunomodulatory drugs (90% had exposure to Revlimid ) were enrolled.

Researchers approached the trial to treat patients with the MLN9708 dose identified in the phase I study. If a prespecified degree of response was not seen after 2 or 4 cycles, dexamethasone would then be added. There is no data from the phase I study regarding the combination of MLN9708 and dexamethasone, so researchers set out to answer both questions.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD